AVX Share Price

Open 0.03 Change Price %
High 0.03 1 Day 0.00 0.00
Low 0.03 1 Week 0.00 0.00
Close 0.03 1 Month 0.00 0.00
Volume 121428 1 Year 0.00 0.00
52 Week High 0.04
52 Week Low 0.02
AVX Important Levels
Resistance 2 0.03
Resistance 1 0.03
Pivot 0.03
Support 1 0.03
Support 2 0.03
ASX Australia Most Active Stocks
DUE 3.02 1.00%
DUE 3.02 1.00%
NWE 0.01 0.00%
NWE 0.01 0.00%
NWE 0.01 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BLY 0.03 -25.00%
LYC 0.18 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
ADX 0.02 100.00%
ADX 0.02 100.00%
ADX 0.02 100.00%
HHM 0.02 100.00%
AOK 0.02 100.00%
BNV 0.03 50.00%
PMQ 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
More..
ASX Australia Top Losers Stocks
RRP 0.08 -90.59%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
QSS 0.01 -50.00%
GDY 0.01 -50.00%
AGJ 0.03 -40.00%
AGJ 0.03 -40.00%
More..

Avexa Ltd (ASX: AVX)

AVX Technical Analysis 1.5
As on 9th Dec 2016 AVX Share Price closed @ 0.03 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.03 & Buy for SHORT-TERM with Stoploss of 0.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
AVX Target for September
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
AVX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.avexa.com.au
AVX Address
AVX
61-63 Camberwell Road
Level 1
Hawthorn East, VIC 3123
Australia
Phone: 61 3 9208 4300
Fax: 61 3 9208 4146
AVX Latest News
Interactive Technical Analysis Chart Avexa Ltd ( AVX ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Avexa Ltd
AVX Business Profile
Avexa Limited, a biotechnology company, discovers and develops anti-infective pharmaceutical medicines for the treatment of human infectious diseases. The company’s research programs primarily focus on the discovery of medicines for the treatment of the diseases caused by human immunodeficiency virus (HIV) and vancomycin-and methicillin-resistant bacteria. Its primary project includes apricitabine (ATC) for the treatment of drug resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The company was founded in 2004 and is based in Hawthorn East, Australia.